In vitro activity of fosfomycin against mucoid and non-mucoid Pseudomonas aeruginosa strains.

Objectives: Pseudomonas aeruginosa is the most frequent infectious agent in cystic fibrosis patients. P. aeruginosa resistance to first line antibiotics limits therapeutic options, but the therapeutic potential of older generation antibiotics, such as fosfomycin is under investigation.